Core Insights - Merck's acquisition of Terns Pharmaceuticals is primarily focused on TERN-701, a next-generation allosteric TKI for chronic myeloid leukemia (CML), which is expected to address unmet needs in the treatment landscape [2][4][6] Company Strategy - Merck's strategy emphasizes a science-led approach to business development, aiming to diversify its pipeline, particularly in oncology, with over 20 anticipated new growth drivers projected to represent a combined commercial opportunity exceeding $70 billion by the mid-2030s [3][4] Acquisition Details - The acquisition of Terns is valued at approximately $6.7 billion, with Merck agreeing to pay $53 per share, and the deal is expected to close in the second quarter of 2026, pending regulatory approvals [7][19] - Merck plans to account for the acquisition as an asset acquisition, anticipating a $5.8 billion R&D charge in 2026 and a negative EPS impact of approximately $0.17 in the first year [5][19] Product Potential - TERN-701 is positioned as potentially "best-in-class," with early clinical data showing promising efficacy and tolerability compared to existing TKIs, including higher rates of major molecular response (MMR) and deep molecular response (DMR) [6][9][10] - The drug targets an allosteric site on the ABL protein, aiming to overcome resistance mutations and minimize off-target effects, which could support higher dosing and more complete inhibition [8][10] Market Opportunity - CML is a chronic disease with an increasing prevalence, with an estimated 18,000 new patients diagnosed annually in the U.S., key European markets, and Japan [14] - Merck anticipates that TERN-701 could become a significant growth driver starting in the early 2030s, with a multibillion-dollar revenue potential [15] Competitive Landscape - Merck does not foresee significant barriers to market access for TERN-701, even amid generic competition for earlier-generation TKIs, and expects that differentiated clinical data will support its uptake [16]

Summary of Terns Pharmaceuticals Conference Call Company Overview - Terns Pharmaceuticals, founded in 2017, focuses on precision oncology, specifically developing small molecule TERN-701 for chronic myeloid leukemia (CML) [3][4] - TERN-701 has shown unprecedented efficacy, demonstrating 2-3 times the efficacy compared to other agents with a differentiated safety profile [3][12] Industry Context - The chronic myeloid leukemia (CML) market has a significant unmet need, particularly in patients who do not achieve major molecular response (MMR) [5][4] - Current treatments, including imatinib and asciminib, have limitations, with over 75% of patients not responding adequately to the best available therapies [5][6] Key Findings from Recent Data - TERN-701 achieved a 75% MMR in patients at doses of 320 mg and above, with deep molecular response rates exceeding 30% [11][12] - The safety profile of TERN-701 is favorable, with low rates of cytopenias and no significant adverse events compared to asciminib [12][13] - TERN-701 has shown efficacy in asciminib-refractory patients, a critical indicator of its potential superiority [15][27] Competitive Landscape - Asciminib has gained approximately 25% market share in the frontline setting, with expectations to reach 50% [6][7] - TERN-701 is positioned as a potential best-in-disease drug due to its efficacy, safety, and lack of food effect, which is crucial for patient adherence [27][40] - The company anticipates that TERN-701 will outperform asciminib in frontline settings, where newly diagnosed patients are generally easier to treat [32][40] Development Plans - Terns Pharmaceuticals plans to conduct a registrational study for TERN-701 in a second-line plus population, with a control arm of a physician's choice 2GTKI [84][86] - A frontline study is also planned, potentially comparing TERN-701 against imatinib or asciminib [86][88] - The company aims to finalize dose selection and engage with the FDA for guidance on study design by mid-2026 [43][82] Financial Position - Terns Pharmaceuticals has secured funding that positions it well for commercialization and launch of TERN-701 in the second-line plus setting [93][94] Additional Insights - The absence of a food effect with TERN-701 is a significant advantage, as many patients struggle with dietary restrictions associated with other therapies [49][55] - The company is exploring a mutation-specific cohort in its studies to address patients with specific genetic mutations, such as T315I [66][72] Conclusion - Terns Pharmaceuticals is poised to make a significant impact in the CML treatment landscape with TERN-701, addressing critical unmet needs and positioning itself against established therapies like asciminib and imatinib. The upcoming studies and FDA interactions will be pivotal in shaping the future of TERN-701 in the market [40][93]

Summary of Terns Pharmaceuticals Conference Call Company Overview - **Company**: Terns Pharmaceuticals - **Product**: Tern 701, an investigational next-generation oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) treatment [2][41] Industry Context - **Disease**: Chronic Myeloid Leukemia (CML) - **Current Treatments**: First-generation and second-generation active-site tyrosine kinase inhibitors (TKIs) like Imatinib and Asciminib - **Market Need**: Significant unmet need for improved efficacy, safety, and tolerability in CML treatments, with approximately 40% of patients switching therapies within five years due to inadequate response or side effects [4][5] Key Points from the Call Efficacy and Safety Data - **Tern 701 Efficacy**: - Achieved a 75% major molecular response (MMR) and 36% deep molecular response (DMR) at 24 weeks in the recommended phase two dose range of 320 mg and above [8][31] - In a refractory patient population, 64% MMR was achieved by 24 weeks across all doses, with 75% MMR in patients at higher doses [10][22] - DMR rates are approximately two times higher than those seen with Asciminib [22][34] - **Safety Profile**: - Most treatment-emergent adverse events (AEs) were low-grade, with all grade three AEs being less than 10% [8][41] - No signs of pancreatic toxicity or significant blood pressure changes were observed, differentiating Tern 701 from Asciminib [18][41] Competitive Landscape - **Asciminib**: - First allosteric BCR-ABL inhibitor approved for CML, achieving a 22% market share in the U.S. within three quarters of launch and peak sales estimates revised to over $4 billion [5][6] - Tern 701 is positioned to potentially outperform Asciminib based on early clinical data [6][34] Clinical Trial Insights - **Cardinal Study**: - A two-part multicenter global study enrolling patients with chronic phase CML who have failed prior TKIs [12] - Enrollment has accelerated, with over 85 patients currently participating [3][41] Future Development Plans - **Next Steps**: - Plans to select a single dose for pivotal studies based on ongoing data collection and regulatory feedback [38][41] - Anticipated catalysts include expanded long-term data from the Cardinal study and potential regulatory meetings in 2026 [42][41] Market Opportunity - **Patient Population**: - Approximately 17,000 new CML patients annually in G7 nations, with a significant portion expected to switch to allosteric therapies due to better efficacy and tolerability [39][40] - **Treatment Goals**: - Focus on achieving rapid and deep molecular responses to improve long-term outcomes and quality of life for CML patients [39][52] Conclusion - Tern 701 shows promising efficacy and safety data, positioning it as a potential best-in-disease therapy for CML, with ongoing trials and future studies aimed at confirming its clinical benefits and market potential [41][42]

Core Insights - Terns Pharmaceuticals reported unprecedented Phase 1 efficacy data for TERN-701, indicating a potential best-in-disease profile for chronic myeloid leukemia (CML) treatment [1][2] - The company has a cash position of $295 million, expected to sustain operations into 2028 [1][5] Pipeline Developments - TERN-701 is an investigational allosteric BCR::ABL1 inhibitor for CML, with a major molecular response (MMR) rate of 75% by 24 weeks in the ongoing CARDINAL trial [3][4] - TERN-601, an oral GLP-1 receptor agonist for obesity, showed a maximum placebo-adjusted weight loss of 4.6% but will not proceed further due to adverse events [3][4] Upcoming Milestones - An updated dataset from the CARDINAL trial will be presented at the 67th ASH Annual Meeting on December 8, 2025, with a conference call scheduled for the same day [4][5] Financial Performance - R&D expenses for Q3 2025 were $19.9 million, up from $15.2 million in Q3 2024, while G&A expenses decreased to $7.8 million from $9.8 million [6] - The net loss for Q3 2025 was $24.6 million, compared to $21.9 million in Q3 2024 [7][8] Balance Sheet Highlights - As of September 30, 2025, total assets were $301.7 million, with total liabilities of $17.6 million and stockholders' equity of $284.1 million [10]

TERN-701 Opportunity - TERN-701 is a novel allosteric BCR-ABL TKI in Phase 1 studies, representing a new generation of therapies for CML with superior target coverage, improved kinase selectivity, and high potency against common mutations[16] - TERN-701 has the potential to transform the standard of care for CML by offering enhanced efficacy, minimal off-target activity, optimized dosing, and more rapid and deeper levels of response, potentially leading to treatment-free remission[16] - TERN-701 is expected to be the 2nd allosteric TKI to market, differentiating itself from asciminib[78] CML Market and Treatment Landscape - Approximately 10,000 new CML cases are diagnosed in the U S annually[10] - The U S CML prevalence is approximately 110,000 and is expected to triple by 2040[10] - Around 40% of CML patients switch therapy within 5 years due to intolerance or resistance[10] - About half of CML patients do not achieve deep molecular response (DMR) by 4 years after switching to a second treatment[10] - Allosteric inhibitors represent the latest evolution in CML treatment, with asciminib being the first approved allosteric BCR-ABL inhibitor[12] Clinical Development and Data Interpretation - Baseline BCR-ABL levels impact the speed and attainment of MMR in relapsed/refractory (R/R) CML patients; patients with baseline BCR-ABL of >10% had the lowest molecular response rates to asciminib in Phase 1[38, 42] - Terns' initial Phase 1 data for TERN-701 will comprise patients with shorter treatment duration compared to precedent initial Phase 1 data disclosures[64] - Interim dose escalation data for TERN-701, expected in December, will include an estimated 10-20 enrolled patients, with 5-10 patients having ≥3 months of treatment across at least 2 dose levels[66] Future Strategy - TERN-701 has broad anticipated opportunity across 1L and 2L, with the potential to split 1L allosteric share and capture 2G TKI intolerant/resistant patients[76, 77] - Subsequent readout in 2025 is anticipated to show 6-month data and inform potential registrational trial[79]